Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sorafenib to treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)

A technology for cerebral vasospasm and subarachnoid space, which can be used in cardiovascular system diseases, drug combinations, active ingredients of heterocyclic compounds, etc., can solve the problems of reduced bioavailability of sorafenib, and achieve the effect of preventing and treating cerebral vasospasm

Inactive Publication Date: 2012-01-04
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Compared with oral solution, the relative bioavailability of Sorafenib tablets is 38% to 49%; high-fat diet can reduce the bioavailability of Sorafenib by 29%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sorafenib to treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)
  • Application of sorafenib to treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)
  • Application of sorafenib to treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Effect of BAY 43-9006 on cerebral vasospasm after SAH

[0040] Materials and methods

[0041] 1. Materials

[0042] 1. Main reagents and medicines

[0043] Trizol total RNA extraction reagent was purchased from U.S. Invitrogen; diethyl pyrocarbonate (DEPC) was purchased from U.S. Sigma; M-MLV reverse transcriptase was purchased from U.S. Promega; Taq DNA polymerase was purchased from U.S. New England Biolabs; dNTPs were purchased from NewEngland Biolabs, USA; six random primers were purchased from Promega, USA; SYBR Green I was purchased from Takara, Japan; chloroform was purchased from Shanghai Chemical Reagent Company; isopropanol was purchased from Shanghai Chemical Reagent Company; absolute ethanol was purchased from Shanghai Chemical Reagent Company.

[0044] Rabbit anti-phospho-ERK1 / 2 (Thr202 / Tyr204) antibody was purchased from US cell signaling company; rabbit anti-IkB-α (C-21) was purchased from US Santa Cruz company.

[0045] PCR primers: The cDNA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of sorafenib shown in a formula (I) to the preparation of a medicinal composition for treating cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Animal experiments prove that BAY 43-9006 has the effect of obviously inhibiting the CVS after the SAH, and can be used for improving the CVS after the SAH.

Description

technical field [0001] The invention belongs to the technical field of new uses of medicines, and specifically relates to the application of sorafenib in the treatment of cerebral vasospasm after aneurysmal spontaneous subarachnoid hemorrhage. Background technique [0002] The annual incidence of spontaneous subarachnoid hemorrhage (SAH) is about 6-16 / 100,000 people, accounting for about 6-8% of the total incidence of stroke. Intracranial aneurysm rupture is the main cause of spontaneous SAH. reason. Cerebral vasospasm (CVS) is a common potentially disabling and fatal complication after aneurysmal SAH. For decades, many scholars have conducted a lot of basic and clinical research on the pathological process of CVS formation, but its exact mechanism is still not completely clear. Nuclear factor κB (Nuclear factor-κB, NF-κB) plays an important regulatory role in inflammatory responses, and activated Raf-1 kinase promotes the activation of NF-κB by promoting the degradation o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/44A61P35/00A61P9/00A61P9/10
Inventor 王中陈罡张健周岱
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com